3 Stocks to Buy for an AI Chip Recovery

The article highlights sharp declines in AI-linked chip stocks despite improving fundamentals: SOXX is down 30% from its June peak, China’s STAR50 is down 40%, and KLA, Marvell, and Lam Research shares have each fallen roughly 47%–50% from recent peaks. The author sees potential upside in all three, citing KLA’s more than 40% growth implied by recent results and December guidance, Marvell’s 37% revenue growth to $2.74 billion and raised fiscal 2027–2028 guidance, and Lam’s 54% revenue growth to $8.2 billion, while flagging supply constraints and China exposure at Lam and merger-related selling pressure at Marvell. These are the author’s and a quantitative system’s bullish views, not a report of confirmed recoveries; the article also notes continuing risks, including possible U.S.-China trade tensions.

Analysis

The opportunity is not simply “AI stocks are cheap”; it is whether capex demand converts into equipment revenue and per-share earnings quickly enough to outrun cyclical multiple compression. KLA offers the cleaner exposure to rising process complexity, while Lam’s reported delivery constraints make backlog conversion—not demand alone—the near-term proof point. If shipments slip again, estimates can be cut even with a healthy order book. China exposure adds an asymmetric policy risk to Lam; an export restriction could strand otherwise strong demand.

Marvell has a distinct event-driven setup: merger-arbitrage hedges can create temporary selling in the acquirer, but any unwind is not a substitute for validating deal economics. The article’s stated transaction value and exchange ratio should be checked against definitive filings before attributing the drawdown to hedge flows. Even if the short pressure fades, issuance and integration can dilute per-share upside; long-dated management targets are not a near-term valuation floor.

Contrarian point: oversold rebounds cited in the article are weak evidence of repeatable alpha, and a quant signal is not independently verifiable here. The more useful signal is estimate revisions relative to actual shipment growth. Over 1–3 months, watch guidance, backlog conversion, merger documentation, and semiconductor-equipment order trends. Over 6–18 months, the thesis depends on sustained AI infrastructure spending and increasing process intensity. Broad risk-off or capex cuts could keep all three names correlated despite company-specific execution.

Key Decisions for Investors

• KLAC: Consider a staged long on evidence of stabilization rather than chasing a sharp bounce. The thesis is relative resilience from process-control intensity; falsify it if forward estimates turn down or customer capex guidance weakens materially. Keep sizing mindful of semiconductor-cycle beta.
• LRCX: Treat as a watch/conditional long, not an immediate catch-up trade. Require evidence that delayed deliveries are shipping and estimates are holding; reassess promptly if constraints persist into the next reporting period. Track U.S.-China export actions as a discrete downside catalyst.
• MRVL: Do not buy solely on the claimed hedge-fund unwind. First verify the definitive Lumentum consideration, exchange ratio, approvals, and pro-forma share count. If terms confirm the mechanical-pressure narrative and operating guidance remains intact, consider a small staged position; a deal break, worse dilution, or weaker customer demand invalidates it.
• Avoid a broad-based dip-buy across memory and chip equipment on the article’s rebound statistics. For MU and SK hynix, wait for evidence that memory pricing and earnings revisions have stabilized; renewed estimate cuts would argue the drawdown is not merely positioning.